METHOD AND SYSTEM FOR INFECTION CONTROL IN AN ACCESS-RESTRICTED AREA
Patent Information
- Application Number
- DE502021005805
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-08-18
- Filing Date
- 2021-03-18
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2041-03-18
AI Technical Summary
Current infection protection measures in access-restricted areas are inadequate, particularly during pandemics, as they often require significant restrictions and are not economically sustainable, and existing testing methods are invasive, costly, and inefficient.
A system comprising a test device, input interface, sample database, release database, release management system, reading device, and signaling device that quickly and cost-effectively evaluates samples for pathogens, granting release authorizations based on test results, allowing controlled access to restricted areas while maintaining anonymity and minimizing harassment.
This system significantly enhances infection protection by reducing the risk of undetected spread, minimizing economic and social disruptions, and maintaining safety with efficient, non-invasive testing protocols, especially in areas where social distancing is challenging.
Description
[0001] The invention relates to a system and a method for infection protection in an access-restricted or access-controlled area.
[0002] During an epidemic or pandemic, infection control is particularly important. It is crucial to contain the spread of a pathogen, usually a virus, as effectively as possible. One example of such a virus is SARS-CoV-2, which causes the lung disease COVID-19 and spread globally in early 2020.
[0003] Particularly problematic are pathogens that pose a risk of infection even before the first symptoms indicate illness. For example, a COVID-19 patient can infect others several days before the first signs of illness appear. People with recently diagnosed symptoms generally shed the highest number of viruses around the time of symptom onset, and thus have the highest potential for infection. Furthermore, COVID-19 in particular often presents with minor symptoms, often without fever. This means that even a (still) asymptomatic person can infect others. In 2020, this resulted in a high reproduction rate (R0) (the average number of other people infected by one infected person) of over 2.5.The R0 was not the same for all infected individuals, but showed considerable differences between individuals, ranging from barely infecting others to becoming "superspreaders." The impossibility of detecting infected individuals using traditional detection methods such as digital temperature checks, combined with the extremely rapid and undetected spread of SARS-CoV-2 in 2020, led to large parts of public life around the world being shut down or at least significantly restricted in order to halt the spread through extensive contact restrictions and to make it manageable again through contact tracing of infected individuals.
[0004] Many attempts are being made to protect against infection through curfews, travel bans, border closures, school closures, working from home, social distancing, hygiene measures, sneezing etiquette, face masks, and other measures. While these measures have been effective overall, they are incompatible with a free society and free economic activity in the long term. Wearing face masks alone is demonstrably insufficient, and in many areas such as wellness centers, swimming pools, or holiday resorts, wearing face masks is hardly or not at all possible. Therefore, in practice, such facilities are usually closed completely or subject to significant restrictions. This represents considerable economic damage for the operators of such facilities and, on the other hand, severely restricts the activities of those affected.Other areas with potentially controlled access, such as airports, airplanes, schools, retirement homes, hospitals, or large events (sports, concerts), are also inadequately protected by simply wearing face masks. In many of these places, social distancing measures can only be implemented to a limited extent. Thus, a significant residual risk of undetected renewed spread remains once the strict protective measures are relaxed.
[0005] The problem would be significantly more manageable if, for each area with possible access control, up-to-date information were available on a timely basis, indicating which person entering the area is currently spreading viruses and thus potentially infecting other contact persons. These systems, when appropriately linked to other digital systems for identifying the specific location, could significantly narrow down potential contact persons and quarantine them before they infect further individuals. Even the spread of a "superspreader" could be nipped in the bud. Since the vast majority of people entering such an area do not spread viruses, the general rule would be to allow full clearance. However, the traditional method of screening with a nasopharyngeal swab and individual sample testing is a highly inconvenient, disproportionately invasive, labor-intensive, and costly procedure during a period when the pandemic is waning.
[0006] Document US2002082859 A1 discloses a system in which a person's access to an amusement park is controlled based on the person's health status. Document US2008206767 A1 discloses a system in which the spread of an infection in a hospital is monitored.
[0007] The present invention is based on the object of designing and developing a system and method of the type mentioned above in such a way that infection control in a restricted-access area is possible without significant restrictions and at economically justifiable costs. It is desirable to achieve minimal disruption to persons entering the area and a substantial preservation of anonymity. The invention is defined in the appended claims.
[0008] According to the invention, the above object is achieved by the features of claim 1. The system in question comprises: a test device for testing a sample for the presence of at least one pathogen in the sample, wherein at least a portion of the sample originates from a person who is located in the restricted-access area or who wishes to enter the restricted-access area; an input interface for entering a test result obtained by the test device by testing the sample; a sample database configured to assign a sample to an identification code and / or a person; a release database configured to assign a release authorization to an identification code and / or a person; a release management system configured to compare the test result entered into the input interface with a target result and, upon receipt of a desired comparison result, to set a release authorization in the release database using the sample database;a reading device for obtaining a read-out identification code by reading out an identification code encoded in an identification means, an interrogation device designed to read out an existing or non-existent release authorization from the release database based on the read-out identification code, and a signaling device that is communicatively connected to the interrogation device and designed to signal a release of the access-restricted area when a release authorization is present.
[0009] In further training, the use of suitable pre-analytical and analytical procedures, by analyzing collective samples or multiple analyses of the same sample for different pathogens, increases efficiency when processing individual samples is correspondingly cost-intensive.
[0010] In procedural terms, the above problem is solved by the features of claim 8. Accordingly, the method in question comprises the steps: Taking a sample from a person who is in the restricted-access area or wishes to enter the restricted-access area, testing the sample for the presence of at least one pathogen in the sample to obtain a test result, setting a release authorization in a release database if a comparison of the test result with a target result provides a desired comparison result, reading out an identification code using a reading device to obtain a read-out identification code, wherein the read-out identification code is encoded in an identification means, reading out a release authorization from the release database for the read-out identification code and signaling a release of the restricted-access area by means of a signaling device if a release authorization for the read-out identification code is present.
[0011] It was initially recognized that population-wide testing for infection is not practical. Even if sufficient laboratory capacity and reagents are available, this approach would entail considerable and unjustifiable effort. However, the invention recognizes that there are areas where testing is practical, namely areas that already have restricted access or that can be converted into restricted access areas with little effort. These areas can include, for example, areas where there is an increased risk due to the gathering of large numbers of people (e.g., airports, ski resorts, football stadiums, workplaces - if maintaining social distancing is not technically feasible), or places where healthy people come into contact with people at very high risk of infection (e.g., retirement homes, nursing homes, hospitals, doctor's offices).In these areas, a significant improvement in infection protection can be achieved by the system and method according to the invention.
[0012] For this purpose, the system according to the invention comprises a test device, an input interface for entering a test result, a sample database, a release database, a release management system, a reader, an interrogation device, and a signaling device. The test device is designed to test a sample for the presence of at least one pathogen in the sample. This pathogen can be a virus, for example SARS-CoV-2. The tested sample originates at least in part from a person who is located in the restricted-access area or who wishes to enter the restricted-access area. The input interface is used to enter a test result obtained by the test device by testing the sample. The sample database is designed to assign a sample to an identification code and / or a person.The release database is designed to assign a release authorization to an identification code and / or a person. The release management system is designed to manage release authorizations in the release database, in particular to set and revoke them. For this purpose, a test result entered into the interface is compared with a target result. Upon receipt of a desired comparison result, the release management system enters a release authorization into the release database. In doing so, the release management system accesses the sample database, in particular to determine an assignment of the sample to an identification code and / or a person. With these components of the system, it can be achieved that a sample is evaluated and, if the desired result is obtained, a release is granted.
[0013] This granted authorization can be used for a later release of a restricted-access area. For this purpose, the system has a reader designed to obtain a read-out identification code by reading an identification code encoded in an identification means. This identification means serves to identify the person from whom at least part of the sample was taken. Such an identification means can be formed by a wristband with a barcode, QR (Quick Response) code or RFID (Radio Frequency Identification) chip, a chip card (for example, an identity card with an RFID chip), a magnetic stripe card, an NFC (Near Field Communication) identifier (for example, from a smartphone or smartwatch), and / or the like. It should be ensured that the identification means can be clearly assigned to a person.This can be achieved, for example, by preventing the means of identification from being transferred from one person to another without damage, such as through a predetermined breaking point on a wristband. It is also conceivable that a biometric feature, such as facial recognition or a fingerprint, could be used to identify the person. This is particularly advantageous when using a smartphone with an associated app.
[0014] Regardless of the design of the identification device, the reader transmits a read-out ID to an interrogation device, which queries whether a release authorization is entered in the release database for the read-out ID. If a release authorization is present, the signaling device signals release of the restricted access area. If no release authorization is present, release is denied.
[0015] The databases, especially the sample database and the release database, can be implemented in a variety of ways. It is important that the database can ensure the required allocation. Whether this allocation takes the form of a simple table or a complex database system is of secondary importance for the present invention.
[0016] Samples can also be collected in various ways, preferably from the nasopharynx. The sample can be collected by pharyngeal lavage, which is then placed directly into a suitably sized sample tube, or, for example, into a small sample tube using a straw. However, the sample can also be collected by wiping the oropharynx with a swab or using a nasal rinse solution (nasal drops followed by spitting or dispensing the nasal rinse solution through a straw). Suitable methods are well known in practice. A sample can be treated with a virus-stabilizing solution for longer transport to ensure that the quality of the sample is not compromised even during transport from the sampling site to the testing facility. A sample should be identifiable.This can be achieved by having a sample container (e.g. a sample tube) carry a sample identifier, for example in the form of a barcode or a QR code, which is attached to the outside of the sample container.
[0017] The system according to the invention is particularly useful when the testing device delivers a large number of test results quickly and cost-effectively. This can be achieved in various ways. Rapid tests can also be used. For example, for the identification of individuals excreting SARS-CoV-2, testing devices are available on the market that deliver a test result within 30 minutes. In one embodiment, an analysis using conventional PCR (polymerase chain reaction) is used, or multiplex PCR is used if different pathogens are to be detected simultaneously. This can be important if, for example, other potentially dangerous pathogens such as influenza are circulating parallel to a second wave of SARS-CoV-2 spread, which require different public health measures and population epidemics, but both are accompanied by similar clinical signs in the initial stages.
[0018] Since these tests are generally expensive for individual analysis, a further development of the procedure involves "pooling." This involves drawing an aliquot from several individual samples using an aliquoting device, with each aliquot usually measuring in the range of a few milliliters or less. The aliquots obtained in this way are mixed by a mixing device, thus creating a mixture of several aliquots. This mixture is then submitted to the testing device as a sample, which then tests the mixture. This approach is based, on the one hand, on the fact that some testing methods—for example, the PCR method—are so sensitive that even small amounts of a virus can be reliably detected. On the other hand, this approach is based on the assumption that a negative result can be expected in many cases.If no virus can be detected in the mixture of multiple aliquots, all of the original samples can be considered virus-free. If the mixture produces a positive or indeterminate result, all of the individual samples from which aliquots were taken must be retested. Since the aliquots only represent a portion of the individual samples, this retesting is easily possible. Despite any retesting that may be necessary, the effort is significantly reduced in this way. For example, if 10,000 individual samples need to be tested and PCR analysis is used, an aliquoting ratio of 1:32 (i.e. 32 aliquots are mixed) reduces the testing effort for PCR analyses to 313 samples if all samples are negative, to 345 samples if one of the 10,000 individual samples contains the virus, to 377 samples if two individual samples are positive, and so on. It can be seen that pooling significantly reduces the testing effort.
[0019] The larger the number of mixed aliquots, the more testing effort can be saved. However, if "too many" aliquots are mixed, a virus-contaminated individual sample may no longer be reliably detected. In one embodiment, the mixture of multiple aliquots consists of more than 10 aliquots. In another embodiment, the mixture of multiple aliquots consists of more than 20 aliquots. In yet another embodiment, up to 100 aliquots are mixed in the mixture of multiple aliquots. In another embodiment, the mixture of multiple aliquots consists of 32 aliquots.
[0020] Aliquoting in the context of the system according to the invention means that a sample to be examined contains parts of several individual samples.
[0021] If no tested pathogen is found in a mixture of multiple aliquots, it can be assumed – provided the number of aliquots in the mixture is not too large – that none of the individual samples is contaminated with the pathogen. Therefore, a comparison of the test result for the mixture with a target result can be considered representative for all individual samples mixed in. Therefore, in a further development, the release management system is configured to compare the test result for a mixture of multiple aliquots with a target result. If the comparison yields a desired comparison result, for example, "no finding," the release management system can set a release authorization for all individual samples. For this purpose, the release management system can, in turn, access the sample database.If the comparison does not lead to a desired comparison result, a test for all individual samples can be initiated - for example, through the release management system.
[0022] In one embodiment, the test device has an output device with which a test result can be output. How such an output device is specifically designed depends on the respective test device. In one embodiment, the output device is a viewing window, a signal light or a display that visually presents a test result. In this case, the test result can be entered manually into the input interface. In another embodiment of the output device, this is formed by an output interface that can output a test result as an analog or digital signal. In this case, the input interface can be designed as a corresponding interface into which a test result output by the output device can be entered.
[0023] Accordingly, the input interface can be designed in various ways. The only essential requirement is that information that can be interpreted as a test result can be entered via the input interface. In one embodiment, the input interface can comprise a keyboard into which a test result is entered. In another embodiment, the input interface can be formed by a field on a screen display that can be selected by a mouse click or a tap on a touch-sensitive display. In yet another embodiment, the input interface can be formed by an interface into which electrical or optical signals are entered, wherein the signals encode a test result to be entered.
[0024] The signaling device can also be designed in different ways. It is important that the signaling device is capable of signaling release. How this is done specifically is secondary. In one embodiment, the signaling device is designed for optical signaling. This can be done, for example, by a display or a light that indicates release. In one embodiment, the signaling device is designed for acoustic signaling. Release can be indicated by a first acoustic signal and non-release can be indicated by a second acoustic signal, whereby the first acoustic signal and the second acoustic signal should be clearly distinguishable from one another. In one embodiment, the signaling device is designed for mechanical signaling.This can be done, for example, by unlocking a turnstile or opening a sliding door or lock. The signaling device can also combine optical, acoustic, and / or mechanical signaling.
[0025] For many pathogens, the risk of infection to others immediately after infection is low or practically nonexistent. Only when the pathogen has multiplied sufficiently in an infected person does the risk of infection to other people increase. Therefore, the release management system can be trained in advanced training to revoke a release authorization set in the release database. This revocation of a release authorization can occur after a specified period of time, for example, 24 hours or 2 days, and / or after a specified time, for example, midnight or 3 a.m. In this way, it can be ensured that a release authorization, once granted, only remains active as long as infection protection is guaranteed with a high degree of probability.
[0026] In one embodiment, the process of taking a sample, testing the sample, and granting a release authorization is repeated regularly. This ensures that a potential infection of a person does not lead to a reduction in infection protection.
[0027] In one development, the system according to the invention is designed as a distributed system, wherein the components of the system can interact with one another via a network. Depending on the extent to which the components are distributed, the network can be formed by a local network, for example Ethernet, WiFi, or Bluetooth, to name just a few possible embodiments. Particularly when components are located at greater distances from one another, for example several kilometers apart, the use of the Internet is recommended, with communication being encrypted. Corresponding encryption techniques (for example SSL - Secure Socket Layer) and access systems (for example DSL - Digital Subscriber Line, LTE - Long Term Evolution, or GSM - Global System for Mobile Communication) are well known in practice.By using a distributed system, sampling can take place at a first location, testing the sample at a second location, release management at a third location, and use of the release authorization at a fourth location. This also means that the authorized access area does not have to be in the same building as the sampling location. The authorized access area can be in the same city as the sampling location, in the same region, or in the same country. However, particularly when using the system for air travel, the authorized access area can also be in another country or on another continent, for example to prevent the tested pathogen from being introduced into the destination country.
[0028] In a further development, the system includes an identification database that assigns a person an identification device and / or an identification code encoded in the identification device. The corresponding assignment can be saved when the identification device is issued to the person in question. However, it is also conceivable that the assignment occurs as part of a registration process, for example, when activating an app on a smartphone or tablet.
[0029] In one embodiment of the method according to the invention, an identification code encoded in an identification device can be read before or upon entering the restricted-access area. Using the identification code read in this way, the access database is then queried to determine whether authorization exists for the read identification code. If authorization exists, access to the restricted-access area is granted. This approach is suitable wherever wearing a face mask or maintaining a minimum distance is not possible, or where special infection control measures are required. Examples include a wellness area, a nursing home, a retirement home, or a football stadium.
[0030] In one embodiment of the method according to the invention, an identification code encoded in an identification means can be read out when leaving the restricted-access area. For the identification code read out in this way, a clearance authorization is retrieved from the clearance database. If clearance authorization is available, the restricted-access area may be left in the desired direction. This approach is particularly suitable for transit areas where infection protection can be achieved within the transit area by wearing face masks and maintaining social distancing. If the transit area is to be left in the transit direction, for example, to board an aircraft, the clearance authorization is checked. This ensures that the risk of infection for the tested pathogen is virtually zero in the area behind the transit area.
[0031] In a training course, entering and / or exiting the restricted area can be recorded in a log database. A timestamp and / or a read-out identification code can be logged. This makes it possible to track which people were in the restricted area at the same time.
[0032] In a further development of the method according to the invention, quarantine measures can be triggered if a comparison of the test result with a target result produces an undefined or undesirable comparison result. This can always be appropriate if the test result suggests the presence of an infection with the tested pathogen or if an infection cannot at least be ruled out with sufficient certainty.
[0033] There are now various possibilities for advantageously embodying and developing the teaching of the present invention. For this purpose, reference is made, on the one hand, to the claims subordinate to the independent claims and, on the other hand, to the following explanation of preferred embodiments of the invention with reference to the drawings. In conjunction with the explanation of the preferred embodiment of the invention with reference to the drawings, generally preferred embodiments and developments of the teaching are also explained. The drawings show: Fig. 1 shows an application scenario of an embodiment of a system according to the invention or a method according to the invention in connection with a ski area, Fig. 2 shows an application scenario of an embodiment of a system according to the invention or a method according to the invention in connection with an air journey and Fig. 3 shows an application scenario of an embodiment of a system according to the invention or a method according to the invention in connection with a wellness hotel.
[0034] The invention enables a cost-effective and practical method for ensuring the safety of visitors and employees through targeted testing of throat rinse solutions or samples from the nasopharynx obtained by other means in locations with potentially feasible access controls during times of epidemic spread of an infection. The principle is based on the fact that people infected with the SARS-CoV-2 virus, for example, are particularly contagious shortly before the onset of symptoms. Being particularly contagious means that the mucous membranes of the nasopharynx release large numbers of viruses and spread them through breathing or coughing, but also through saliva.
[0035] By gargling with a suitable rinsing solution, a few milliliters of sample are collected from each person upon entry or earlier on the same day. The identity of the sample donor is securely linked to the barcoded sample tube by a scanner for future tracking.
[0036] The samples are promptly transported to an analysis laboratory in a virus-stabilizing solution. There, an aliquot is taken from several samples (up to 32 samples, based on current knowledge) and mixed with the other aliquots in a PCR reaction for the virus of interest (e.g., SARS-CoV-2). If the mixed sample shows no presence of the virus, all original samples are considered normal. If the mixed sample shows the presence of the virus, all original samples must be retested individually. Since a PCR reaction on conventional automated analyzers takes a few hours, all potentially positive samples can be identified by the end of the working day.
[0037] If a positive person is found, they can be informed immediately that evening, and they and all other contact persons can be quarantined. Since contact persons themselves become contagious only a few days after contact with the infected person who is spreading the pathogen, this undoubtedly interrupts the spread. If one of the people screened develops symptoms of illness the day after the entry check, it is firstly ensured that this person is extremely unlikely to have a SARS-CoV-2 infection, but that the illness must be caused by another pathogen.
[0038] The procedure optionally provides for the retained sample from the previous day, the time of peak infection, to be tested using multiplex PCR (i.e., simultaneous testing for various pathogens) followed by genomic next-generation sequencing to positively determine the presumed cause of the disease. This option further contributes to safety by distinguishing between the rather rare, expected event of a SARS-CoV-2 infection and the much more frequently expected infections with other pathogens, ranging from respiratory diseases and flu-like infections to influenza.
[0039] The method is therefore particularly suitable when the initial probability of the dangerous pathogen being sought is rather low, as in the current situation in Europe with SARS-CoV-2, but drastic protective measures are necessary due to the danger to the population posed by an undetected spread of infection. The method ensures access security and can be used in combination with other access controls such as scanners and RFID readers in a wide variety of situations, from access to wellness areas in hotels, access to restaurants, access to events, access to sports facilities, including ski resorts, and access to workplaces and production facilities. Especially when aliquoting, the method significantly reduces the burden on those being tested and the costs compared to today's standard testing procedures.
[0040] The method according to the invention eliminates various weaknesses in current routines: it increases response time in the event of outbreaks, it reduces costs, it increases security, it increases reassurance, and above all, it increases the possibility of enabling events with large gatherings where social distancing is difficult, such as travel on wide-body aircraft or concerts, despite the continued presence of the virus in the population. It can be used wherever access control is already provided or can be easily implemented. Wherever other systems perform tracking, such as key cards at ski resorts, these systems can be used to further narrow down the number of possible contacts in the event of a positive test result. The method can be adapted for very low infection rates, for example, by testing only every second or third person (e.g., by date of birth).
[0041] A possible use case is a ski resort, a stadium, or the like. Such a use case is in Fig. 1 outlined. Various readers are available that enable, for example, RFID gating.
[0042] In the example shown, several people 1.1 to 1.8 wish to enter a restricted-access area 2 - in this case a ski resort. Before entering area 2, each person 1.1 to 1.8 provides a sample A to H, whereby an association between person and sample, or between an identification code identifying the person and a sample, is stored in a sample database. The samples are tested for the presence of a pathogen by a testing device, which is symbolically represented by a timeline 3 for laboratory processing. During this time, people 1.1 to 1.8 are in the ski area. For the sake of clarity, only the paths of three people are shown: person 1.1 / sample A, person 1.4 / sample D, and person 1.5 / sample E. To track the paths of the people, several readers 4.1 to 4.8 are distributed in area 2, which read an identification code from an identification device of people 1.1 to 1.8. Readers 4.1 to 4.8 can be configured as RFID gates. The read identification codes are stored with a timestamp in a log database. Some readers (4.3, 4.4, 4.7, 4.8) register that several people are in the same area at the same time.
[0043] At the end of laboratory processing 3, test results are available, indicating that sample E contains the tested pathogen. A sample database can be used to assign sample E to person 1.5 or an identification device worn by that person. Person 1.5 can then be located in area 2 and escorted out of area 2, indicated by the word "STOP!". Using the protocol database, it can be determined whether any contact persons are present. In the example shown, person 1.4 was in the area of reader 4.4 at 10:45 a.m., which could, for example, identify the same gondola of a cable car. This person 1.4 can be informed accordingly.
[0044] Another possible use case is air travel, as in Fig. 2is outlined. Air travelers 1 may be required to provide a throat rinse sample 6 at the security checkpoint 5 after check-in before being allowed to enter the restricted area 2 – in this case, the airport's security area. These samples 6 can be sent to a laboratory and analyzed there using the method described. Pooling can be performed in the laboratory.
[0045] In the lower part of the Fig. 2An example timeline is shown. In period T1, which in this example lasts 15 to 60 minutes, the samples are brought to the laboratory. During period T2 (here 5 to 30 minutes) a preliminary analysis is carried out. In period T3 (here 30 to 180 minutes) the actual testing is carried out, for example using PCR. During period T4 (here 30 to 60 minutes) the results are validated. If a mixture of aliquots shows a positive result, a follow-up analysis of the individual samples in the pool is carried out in period T5. The result is then available after a relatively short time and can be linked to the airline's booking code. Depending on the total time required for laboratory processing, a test result may be available upon boarding an aircraft 7.1 to 7.9 or before / upon reaching the destination airport, and the appropriate action may be taken.
[0046] Within area 2, the boarding pass—an identification means within the meaning of the present invention—could be read at various locations using a reader 4.1 to 4.6. These readers could be located, for example, at the gates and / or other access points. If the boarding pass had to be presented at all possible contact points within the airport, the exact path and contact persons of those affected could be identified by linking the systems. This would ensure rapid containment. For the vast majority of air travelers, for example, on a flight to New York, the captain would contact Island and communicate clearance for all passengers. In the example shown, there is a person on aircraft 7.7 who has tested positive. On the other aircraft, there is no person in whom the tested pathogen could be detected.
[0047] If, due to appropriate progress in laboratory procedures, a test result is available within 30 minutes of sample collection, the test result or clearance can be requested during boarding. In this case, it is conceivable that only passengers with a negative test result will be allowed to board aircraft 7.1 to 7.9. This ensures with a high degree of certainty that only non-infectious travelers have boarded the aircraft once boarding is complete. Protective measures during the flight can then be dispensed with.
[0048] Another possible use case is hotel stays, as in Fig. 3 is outlined. A corresponding process could look like this: 1. Guests 1 arriving at the hotel receive an ampoule box 8 with collection tubes for several days, throat rinse solution for several days, and straws for transferring the throat rinse solution into a sample tube 9 upon check-in. 2. At time t1, guests 1 gargle with the throat rinse solution and transfer the sample into a sample tube 9. Guests 1 submit the first sample on the day of arrival. If the sample is submitted after 9:00 a.m., the general protection and hygiene regulations apply to these guests on the day of arrival. 3. At time t2, the reception or a correspondingly set-up station receives the sample tube 9 bearing a barcode 10 in compliance with hygiene regulations and anonymously creates the guest via a website. Optionally, the guest can also register in person, for example, using a smartphone 11. 4. The reception scans the barcode of the sample tube. The information is stored in a sample database. 5.When the sample is submitted before 9:00 a.m., the reception scans an industrially prefabricated wristband - identification means 12 - also bearing a (different) barcode and hands it over to the guest. Alternatively or additionally, a QR code on the smartphone 11 can form an identification means 12'. 6. The reception enters the room number and the guest's consecutive number in the room (Guest 1, Guest 2, etc.) into the software. This maintains the complete anonymity of the guests. The assignment is stored in an identification database. 7. Upon request, the reception can also enter a valid email address for the guest, which then allows the guest to log into the system and, for example, receive the test result early or to enter their own symptoms if symptoms occur. This facilitates further treatment in the rare case of illness (e.g., the common cold).Guests can initially participate anonymously and decide to set up a new login each day. The advantage of the login is that the same code on the wristband can also be displayed on the smartphone, like a boarding pass for airplane check-in. 8. The laboratory will collect the samples after 9:00 a.m. using a shuttle service. 9. At time t3, aliquots are taken from several samples 6 (e.g., 10 to 30 samples) and mixed to form a mixture 13 of the several samples 6. The mixture 13 is fed to a testing device 14, which is located in . Fig. 3is only symbolically represented and can, for example, use a high-throughput PCT or an alternative method. 10. The hotel automatically receives full approval in the system by 3:00 p.m. at the latest, provided all samples are negative (arrow 15). The guest can also be informed separately (arrow 16), for example via their smartphone 11 or by email. In the rare event that this occurs, the hotel receives preliminary information around 3:00 p.m. that at least one sample was positive and that protective measures must therefore be continued (block 17) until the individual sample is confirmed as positive at around 7:00 p.m. If an individual sample is positive, a notification is sent to the affected guest (block 18), who can be identified, for example, by their room number. The affected guest can be quarantined (block 19). Contact persons do not necessarily have to be quarantined, but should exercise caution and be tested daily.The releases are entered as release authorizations in a release database. Sampling, testing, notification, and setting of releases can be repeated daily. 11. The hotel must also test all employees daily, especially those who work in open areas or who may come into contact with guests. 12. From 3:00 p.m. onwards, the hotel can then fully open all areas with access control and forgo the protective measures except for disinfection after the facility closes at the end of the day. Access control 20 is carried out via barcode scanners or another reading device 4. In this example, the identification means 12, 12', i.e. the wristband or the QR code from the smartphone 11, is scanned. If an release is entered in the release database for a read identification code, the guest is granted access to the restricted / access-controlled area (block 21).The system knows all negative samples from that day.
[0049] In principle, it is also conceivable that protective measures would only apply to newly checked-in guests without clearance, and that the restricted areas would be open all day without protective measures to all guests who have already been tested. However, these guests would still be required to provide a sample daily to retain clearance.
[0050] With regard to further advantageous embodiments, reference is made to the general part of the description and to the appended claims in order to avoid repetition.
[0051] Finally, it should be expressly pointed out that the embodiments described above serve only to explain the claimed teaching, but do not limit it to the embodiments. List of reference symbols
[0052] 1 Person 2 Restricted access area 3 Timeline for laboratory processing 4 Readers 5 Security check 6 Sample 7 Aircraft 8 Ampoule box 9 Sample tube 10 Barcode 11 Smartphone 12 Identification device 13 Mixing of multiple samples 14 Testing device 15 Arrow "Hotel, all green" 16 Arrow: "Guest, all green" 17 Positive pool, retesting 18 Notification to guest 19 Quarantine for guest with positive test result 20 Access control 21 Access to restricted access area
Claims
1. System for infection protection in a restricted-access area, comprising: a test device for testing a sample for the presence of at least one pathogen in the sample, wherein at least a portion of the sample originates from a person who is located in the restricted-access area or who wishes to enter the restricted-access area, an input interface for inputting a test result which has been obtained by the test device by testing the sample, a sample database which is configured to associate an identification marker and / or a person with the sample, a release database which is configured to associate a release authorisation with the identification marker and / or the person, a release management system which is configured to compare the test result input into the input interface with a desired result and, when a desired comparison result is obtained using the sample database, to set the release authorisation in the release database, a reading device for obtaining an output identification marker by outputting an identification marker which is encoded in an identification means of the person, a request device which is configured, based on the output identification marker, to output a release authorisation which may or may not be present from the release database and a signalling device which is connected in a communicating manner to the request device and which is configured, when the release authorisation is present, to signal a release of the restricted-access area.
2. System according to claim 1, characterised in that the system comprises an aliquoting device and a mixing device, wherein the aliquoting device is configured to in each case draw an aliquot from a plurality of individual samples, wherein the mixing device is configured to mix the plurality of aliquots into a sample, and wherein the test device carries out a test of the mixture of the plurality of aliquots, wherein the mixture of the plurality of aliquots may comprise more than 10 aliquots, preferably more than 20 aliquots, in a particularly preferred manner up to 100 aliquots, in a very particularly preferred manner 32 aliquots, and / or wherein the release management system is configured to compare the test result for the mixture of the plurality of aliquots with the desired result, and wherein the release management system may additionally be configured, when a desired comparison result is obtained using the sample database, to set the release authorisation for all the individual samples of the mixture.
3. System according to claim 1 or 2, characterised in that the test device is configured to carry out an analysis by means of PCR - Polymerase Chain Reaction.
4. System according to any one of claims 1 to 3, characterised in that the test device comprises an output device for outputting the test result, wherein a test result which is output via the output device is preferably input into the input interface for inputting the test result.
5. System according to any one of claims 1 to 4, characterised in that signalling device is configured for an optical and / or mechanical and / or acoustic display of the release and / or in that the release management system is additionally configured to withdraw release authorisations which have been set in the release database after a predetermined period of time has expired and / or after a predetermined time has been reached and / or in that the system is in the form of a distributed system, wherein components of the system can interact with each other via a network, preferably via the Internet.
6. System according to any one of claims 1 to 5, characterised in that the reading device for outputting the identification means is in the form of a barcode, a QR code - Quick Response Code, an RFID chip - Radio Frequency Identification Chip and / or an NFC identifier - Near Field Communication identifier.
7. System according to any one of claims 1 to 6, characterised in that the system has an identification database which associates the identification means and / or the identification marker encoded in the identification means with the person.
8. Method for identification protection in a restricted-access area, preferably using a system according to any one of claims 1 to 7, comprising the steps of: taking a sample from a person who is located in the restricted-access area or who wishes to enter the restricted-access area, associating the sample with an identification marker and / or with the person in a sample database, testing the sample for the presence of at least one pathogen in the sample in order to obtain a test result, setting a release authorisation in a release database when a comparison of the test result with a desired result provides a desired comparison result, wherein the release database is configured to associate the release authorisation with the identification marker and / or the person, outputting an identification marker by means of a reading device in order to obtain an output identification marker, wherein the output identification marker is encoded in an identification means of the person, outputting the release authorisation from the release database for the output identification marker, and signalling a release of a restricted-access area by means of a signalling device when the release authorisation for the output identification marker is present, wherein the taking of a sample, the testing of the sample, and the setting of a release authorisation can be carried out on a regular basis, preferably daily.
9. Method according to claim 8, characterised in that the set release authorisation is deleted after a period of time has elapsed and / or when a time is reached.
10. Method according to claim 8 or 9, characterised in that, when the identification means is output to the person, the identification means and / or an identification marker encoded in the identification means is stored together with identification data of the person in an identification database.
11. Method according to any one of claims 8 to 10, characterised in that a sample marker is associated with a sample before or after the sample has been obtained, and in that the sample marker is associated with the identification marker and / or the person in a sample database.
12. Method according to any one of claims 8 to 11, characterised in that, before or when entering the restricted-access area, an identification marker which is encoded in the identification means is output by the reading device, in that for the output identification marker the release authorisation is requested from the release database and in that, when the release authorisation is present, access to the restricted-access area is allowed.
13. Method according to any one of claims 8 to 12, characterised in that< / b> the restricted-access area comprises a transit area, in that when leaving the restricted-access area the identification marker which is encoded in the identification means is output, in that for the output identification marker the release authorisation is requested from the release database and in that the restricted-access area can be left in a transit direction only when the release authorisation is present.
14. Method according to any one of claims 8 to 13, characterised in that entering and / or leaving the restricted-access area is detected in a protocol database, preferably in each case together with a time stamp and / or the output identification marker.
15. Method according to any one of claims 8 to 14, characterised in that quarantine measures can be initiated when the comparison of the test result with the desired result provides an undefined or undesirable comparison result.
